Physician profile
Tara Walker
NPI 1730798950
$4,518.60
in general payments reported to CMS, 2019-2025
34 companies · $559 in 2025
The $559 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $767 · 2022: $1,656 · 2023: $969 · 2024: $568 · 2025: $559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,095.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,095.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $899.01 | 2021-2025 | |
| Amgen INC. | $513.44 | 2021-2025 | Evenity, Repatha, Otezla |
| Novo Nordisk INC | $275.79 | 2021-2025 | Rybelsus, Ozempic, Tresiba |
| Pfizer INC. | $243.72 | 2021-2025 | |
| Lilly USA, LLC | $233.33 | 2021-2025 | Mounjaro, Zepbound, Emgality |
| Esperion Therapeutics, INC. | $220.95 | 2021-2025 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $200.92 | 2022-2025 | Farxiga, Airsupra |
| Biohaven Pharmaceutical Holding Company LTD. | $176.86 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $155.21 | 2021-2023 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $149.98 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.93 | 2021-2024 | Jardiance, Jentadueto, Synjardy |
| Glaxosmithkline, LLC. | $108.73 | 2021-2023 | Shingrix |
| Supernus Pharmaceuticals, INC. | $108.38 | 2022-2023 | Qelbree |
| Merck Sharp & Dohme LLC | $94.49 | 2021-2024 | Verquvo, Dificid, Belsomra |
| Corcept Therapeutics | $93.61 | 2025 | Korlym |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $83.29 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $79.36 | 2022 | |
| Sumitomo Pharma America, INC. | $71.31 | 2023 | Gemtesa |
| E.R. Squibb & Sons, L.L.C. | $65.72 | 2021-2022 | |
| Axsome Therapeutics, INC. | $63.75 | 2023 | Auvelity |
| Exact Sciences Corporation | $62.56 | 2023-2025 | Cologuard Collection Kit |
| Ironwood Pharmaceuticals, INC | $62.47 | 2022-2023 | Linzess |
| Lundbeck LLC | $59.34 | 2023-2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $56.36 | 2023-2024 | Rexulti |
| Astellas Pharma US INC | $51.33 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $50.74 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $45.87 | 2021 | |
| Phathom Pharmaceuticals, INC. | $40.68 | 2024-2025 | Voquezna |
| Shield Therapeutics INC | $40.29 | 2022-2023 | Accrufer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.28 | 2022-2024 | Trulance, Xifaxan |
| Tris Pharma INC | $19.12 | 2022 | |
| Sanofi-Aventis U.S. LLC | $17.22 | 2022 | |
| Eisai INC. | $16.21 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.